Form 4: Veracyte SVP, General Counsel Annie McGuire Reports Tax Withholding Stock Transaction
SEC Form 4 Filing
Annie McGuire, SVP, General Counsel of Veracyte, Inc., reports the withholding of shares to cover tax obligations related to the vesting of Restricted Stock Units.
Summary
- On September 2, 2024, Annie McGuire, SVP, General Counsel of Veracyte, Inc., had shares of common stock withheld to cover tax obligations.
- A total of 1,920 shares were withheld at a price of $31.55 per share.
- This transaction does not represent a sale by the reporting person but rather a withholding to satisfy tax obligations related to the vesting of Restricted Stock Units (RSUs).
- The RSUs were granted on February 28, 2022, August 5, 2022, and March 6, 2023.
- Following the transaction, McGuire beneficially owns 93,486 shares of Veracyte common stock.
Sentiment
Score: 7
Explanation: The document reflects a neutral event (tax withholding) related to executive compensation, which is a normal business operation. There is no indication of positive or negative sentiment.
Industry Context
This is a routine SEC Form 4 filing, reflecting a common practice of stock withholding to cover tax obligations upon the vesting of restricted stock units, a typical component of executive compensation in publicly traded companies.
Comparison to Industry Standards
- Stock-based compensation is a common practice among publicly traded companies, particularly in the biotech and healthcare sectors, to align executive incentives with shareholder value.
- Tax withholding on vesting RSUs is a standard procedure, and the number of shares withheld is proportional to the executive's tax bracket and the value of the vested shares.
- Companies like Exact Sciences and Genomic Health (now part of Exact Sciences) also utilize stock-based compensation as part of their executive compensation packages.
Stakeholder Impact
- The transaction has a minimal direct impact on shareholders, as it is a routine tax withholding and does not represent a sale of shares by the executive.
Key Dates
| Date | Description |
|---|---|
| February 28, 2022 | Date of grant for 1,429 Restricted Stock Units. |
| August 5, 2022 | Date of grant for 892 Restricted Stock Units. |
| March 6, 2023 | Date of grant for 1,463 Restricted Stock Units. |
| September 2, 2024 | Date of transaction (stock withholding for tax obligations). |
| September 4, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.